IMT Header

Cambridge Healthtech Institute’s Second Annual
Rational Combination Cancer Immunotherapy
Designing and Implementing Strategies for Increasing the Efficacy of Cancer Immunotherapy by Combining Checkpoint Inhibitors and Biotherapeutics
August 25-26

The clinical and regulatory successes of the PD-1 and CTLA-4 checkpoint proteins are driving a resurgence of interest in immunotherapy as a mainstream form of cancer treatment, with numerous clinical studies exploring the application of these therapeutics in combinations with traditional and experimental agents.  CHI’s 2nd Annual Rational Combination Cancer Immunotherapy takes a forward-looking perspective on the design of drug products and treatment progressions that will build on the knowledge arising from these exploratory trials. The meeting will explore the scientific assumptions, patient diagnostic inputs and historical basis for different immunotherapy combinations – and consider new paradigms for the clinical studies that will evaluate these programs in the progression from research to commercialization. 

Keynote Presentation: Politics and Realities of IO Combination Trial Design

Llew Keltner, M.D., Ph.D., CEO, EPISTAT


Talk Title to be Announced

Omid Hamid, M.D., Director, Melanoma Center, Angeles Clinic and Research Institute

Defining a True Tumor-Specific Epitope for Effective Cancer Immunotherapy

Pramod Srivastava, M.D., Ph.D., Professor, Immunology and Medicine, University of Connecticut School of Medicine; Director, Carole and Ray Neag Comprehensive Cancer Center

Prognostic and Predictive Markers to Support Identification of Effective Immunotherapy Combinations

Kathleen M. Mahoney, M.D., Ph.D., Clinical Instructor, Beth Israel Deaconess Medical Center; Research Fellow, Dana Farber Cancer Institute


Immune Checkpoint Modulation: Rational Design of Combination Strategies

Michael A. Postow, M.D., Assistant Attending Physician, Melanoma and Immunotherapeutics Service, Memorial Sloan-Kettering Cancer Center

Expansion and Activation of T Cells via the Targeting of the Immunosuppressive Ligand Phosphatidylserine (PS): Combination Strategy with Conventional, Targeted, and Checkpoint Inhibitor Therapy

Jeff T. Hutchins, Ph.D., Vice President, Preclinical Research, Peregrine Pharmaceuticals

Use of Pegylated Interleukin 10 (Peg –IL10) as Monotherapy and in Combination with Other Anti-Cancer Agents

Aung Naing, M.D., Associate Professor, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center

Cancer Vaccine/Immune Checkpoint Combinations

Marc Mansour, Ph.D., COO, ImmunoVaccine, Canada

The TAM Receptor Tyrosine Kinase Family and Their Potential to Modulate Macrophage and Dendritic Cell Function Create Opportunities to Combine with T Cell Checkpoint Drugs

Jerry McMahon, Ph.D., President & CEO, Kolltan Pharmaceuticals

Enhanced Efficacy of IL-15-Based ALT-803 Superagonist Complex in Combination with Immune Checkpoint Inhibitors

Hing C. Wong, Ph.D., President and CEO, Altor Bioscience


Interactome Networks and Human Disease: Potential Applications for Cancer Immunotherapy

David E. Hill, Ph.D., Research Associate in Genetics, Center for Cancer Systems Biology, Dana-Farber Cancer Institute

Talk Title to be Announced

Alexander Anderson, Ph.D., Chair, Integrated Mathematical Oncology Program, Moffitt Cancer Center


Regulatory Challenges in Development of Novel Cancer Combinations

Elena Spanjaard, Ph.D., Director, Worldwide Research & Development, Regulatory, Pfizer

Immunotherapy as Personalized Medicine

Ravi Madan, M.D., Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute

For more details on the conference, please contact:
Kent Simmons
Conference Director
Cambridge Healthtech Institute
T: (+1) 207-869-9199

For exhibit & sponsorship opportunities, please contact:
Katelin Fitzgerald
Sr. Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5458